

NEOVASCULAR AGE-RELATED MACULAR DEGENERATION TREATMENTS

Generic	Brand	Strength	Form	Adult Dose
VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) INHIBITORS				
brolicizumab-dblb	Beovu	6mg/0.05mL	soln for intravitreal inj	6mg (0.05mL) once monthly (approx. 25–31 days) for the 1st 3 doses, followed by 6mg (0.05mL) once every 8–12wks
pegaptanib sodium	Macugen	0.3mg per prefilled syringe	soln for intravitreal inj	0.3mg once every 6wks
ranibizumab	Lucentis	6mg/mL (0.3mg), 10mg/mL (0.5mg)	soln for intravitreal inj	0.5mg (0.05mL of 10mg/mL) once a month (approx. 28 days); or 3 monthly doses followed by less frequent dosing (less effective); or 0.5mg every 3mos after 4 monthly doses (less effective). Monitor regularly.
	Byooviz ¹	10mg/mL (0.5mg)	soln for intravitreal inj	
	Cimerli ¹	6mg/mL (0.3mg), 10mg/mL (0.5mg)	soln for intravitreal inj	
	Susvimo ^{1,2}	100mg/mL	soln for intravitreal implant or intravitreal inj	
VEGF INHIBITOR + ANGIOPOIETIN-2 (ANG-2) INHIBITOR				
faricimab-svoa	Vabysmo	120mg/mL	soln for intravitreal inj	6mg (0.05mL) once every 4wks (approx. every 28 ± 7 days, monthly) for the 1st 4 doses, followed by optical coherence tomography and visual acuity evaluations 8 and 12wks later to determine whether to give a 6mg (0.05mL) dose on one of the following 3 regimens: (1) Weeks 28 and 44; (2) Weeks 24, 36 and 48; or (3) Weeks 20, 28, 36 and 44.
VEGF INHIBITOR + HUMAN IGG1				
afibercept	Eylea	2mg/0.05mL	soln for intravitreal inj	2mg (0.05mL) once every 4wks (approx. 28 days, monthly) for the 1st 12wks (3mos), followed by 2mg (0.05mL) once every 8wks (2mos); some may need the monthly dosing after the 1st 3mos. May also treat with 1 dose every 12wks after one year of successful therapy (not as effective); assess regularly.
PHOTOSENSITIZER				
verteporfin	Visudyne ³	15mg per vial	pwd for IV infusion after reconstitution and dilution	Infuse over 10mins at a rate of 3mL/min. Usual dose: 6mg/m ² . After infusion, the second step is activation of verteporfin with light from a nonthermal diode laser. Reevaluate every 3mos and if choroidal neovascular leakage is detected on fluorescein angiography, therapy should be repeated.

NOTES

¹ Biosimilar to Lucentis.

² In patients who have previously responded to at least 2 intravitreal injections of a VEGF inhibitor.

³ Consider for wet AMD patients with persistent intraocular fluid leakage, including anti-VEGF nonresponders.

Not an inclusive list of medications and/or official indications. Please see drug monograph at www.eMPR.com and/or contact company for full drug labeling.